4-(4-((4-氯苯基)(吡啶-2-基)甲氧基)哌啶-1-基)丁酸化合物与苯磺酸(1:1)

更新时间：2024-01-12 11:06:52

4-(4-((4-氯苯基)(吡啶-2-基)甲氧基)哌啶-1-基)丁酸化合物与苯磺酸(1:1)结构式	常用名	4-(4-((4-氯苯基)(吡啶-2-基)甲氧基)哌啶-1-基)丁酸化合物与苯磺酸(1:1)	英文名	4-(4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoicacidcompoundwithbenzenesulfonicacid(1:1)
	CAS号	1415692-17-9	分子量	547.06
	密度	N/A	沸点	N/A
	分子式	C₂₇H₃₁ClN₂O₆S	熔点	N/A
	MSDS	N/A	闪点	N/A

用途

(Rac)-Bepotastine (besilate) 是 Bepotastine (besilate) (HY-A0015) 的非活性异构体,可作为实验中的对照化合物。Bepotastine besilate 是一种具有选择性和口服活性的第二代组胺 H1 受体 (histamine H1 receptor) 拮抗剂,可抑制组胺介导的神经生长因子 (NGF) 表达上调。Bepotastine besilate 可用于过敏性鼻炎,过敏性结膜炎和荨麻疹/瘙痒症的研究。

中文名	4-(4-((4-氯苯基)(吡啶-2-基)甲氧基)哌啶-1-基)丁酸化合物与苯磺酸(1:1)
英文名	bepotastine besilate

描述	(Rac)-Bepotastine (besilate) 是 Bepotastine (besilate) (HY-A0015) 的非活性异构体,可作为实验中的对照化合物。Bepotastine besilate 是一种具有选择性和口服活性的第二代组胺 H1 受体 (histamine H1 receptor) 拮抗剂,可抑制组胺介导的神经生长因子 (NGF) 表达上调。Bepotastine besilate 可用于过敏性鼻炎,过敏性结膜炎和荨麻疹/瘙痒症的研究。
相关类别	研究领域 >> 内分泌信号通路 >> 其他 >> 其他研究领域 >> 炎症/免疫
参考文献	[1]. Kida T, et al. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010 Jul;91(1):85-91. [2]. Kamata Y, et al. Bepotastine besilate downregulates the expression of nerve elongation factors in normal human epidermal keratinocytes. J Dermatol Sci. 2018 Apr 23:S0923-1811(18)30186-5. [3]. Tanizaki H, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol. 2008;145(4):277-82. [4]. Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38.

描述

相关类别

研究领域 >> 内分泌

信号通路 >> 其他 >> 其他

研究领域 >> 炎症/免疫

参考文献

[1]. Kida T, et al. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010 Jul;91(1):85-91.

[2]. Kamata Y, et al. Bepotastine besilate downregulates the expression of nerve elongation factors in normal human epidermal keratinocytes. J Dermatol Sci. 2018 Apr 23:S0923-1811(18)30186-5.

[3]. Tanizaki H, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol. 2008;145(4):277-82.

[4]. Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38.